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Objective: to summarize approaches to the selection of non-inferiority (NI) margins in 
non-inferiority trials and to explore the extent of variation in the selection of NI margins; 
Methods: Non-inferiority trials in stroke, cardiovascular disease, infectious disease and 
diabetes were searched and screened for inclusion on ClinicalTrials.gov. The primary 
outcome of interest was the non-inferiority margin used by trials. Potential factors 
regarding the selection of the NI margins were collected from full-text review. Descriptive 
statistics (counts and proportions) were used to report the patterns in NI margins. When 
appropriate, NI margins were transformed in order to evaluate and compare them. Results: 
In 8 stroke trials (42.1%), time-to-event outcome variables and NI margin expressed as a 
hazard ratio were generally used. The NI margins of hazard ratio ranged between 1.05 and 
2. In 8 studies on coronary artery disease, all utilized in-stent late lumen loss as their 
primary endpoint, with NI margins ranging from 0.11mm to 0.32mm. In 8 NI trials on 
influenza vaccine, geometric mean titers (GMTs) and seroconversion rate were 
consistently used to evaluate the efficacy of vaccine. GMTs ratio of 1.5 and seroconversion 
rates of 10% difference were selected as the NI margins in all trials. Of 19 NI trials in 
diabetes, most (68.4%) used the change in HbA1c from baseline as the primary outcome 
and absolute difference between the changes as the comparison statistic. NI margins ranged 
from 0.3% to 0.5%, but 7 of 13 used a margin of 0.4%. Pooling all 47 trials across these 4 
different disease areas, we found a mean of 1.43 and a 95% two-sided confidence interva l 
from 1.33 to 1.54 on the transformed relative scale for the NI margins. Conclusion: There 
is no evident or consistent pattern on the selection of NI margins and the variation of NI 
margin selection is large both within specific disease area and across different disease areas. 
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Randomized clinical trials (RCTs) are deemed to be the gold standard in 
investigating the efficacy or safety of a new treatment, and there are three major types of 
RCTs based on their purposes: 1) superiority trials, which aim to demonstrate that a tested 
treatment is better than a control; 2) equivalence trials, which aim to demonstrate that a 
tested treatment is similar to an existing treatment within a specified margin; and 3) non-
inferiority (NI) trials, which aim to demonstrate that a new treatment is not worse than the 
existing treatment within a pre-specified margin. NI designs are useful in situations where 
the efficacy of a tested drug is thought to be roughly the same as the comparator and the 
benefits of comparator are known, but the tested drug has additional advantages, such as 
fewer adverse events, easier use, or reduced cost [1]. NI designs can also be used to 
indirectly show the efficacy of a tested drug over a placebo when the use of a placebo is 
unethical such as when an efficacious standard treatment is already available and it would 
be improper for patients in such a trial to be given an inferior treatment [2]. Likewise, NI 
trials can test pharmacologically related compounds to see if they are similarly effective  
[3]. Because of their many strengths, non-inferiority randomized trials are gaining in 
popularity in recent years, especially in the fields of oncology, infectious disease, or 
cardiovascular disease [4]. However, non-inferiority trials also face methodologica l 
challenges in determining the appropriate “non-inferiority margin” – a pre-specified 
amount by which the extent that the test treatment is inferior to the control is not allowed 
to exceed when we intend to prove that the test treatment is not worse than the control. The 
NI margin is thus the largest loss of effectiveness to establish non-inferiority.  
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When conducting a non-inferiority trial, the alternative hypothesis is that the 
outcome of the tested treatment may show slightly less effectiveness to the active control, 
but the difference between the groups is no more than a pre-determined non-inferior ity 
margin. Margins that are chosen to be too large may lead to trials that are easier to complete 
but show purported non-inferiority while potentially being less effective than the 
comparator. General guidance exists on the determination of NI margins. The Internationa l 
Conference on Harmonization (ICH) has published a guideline entitled Guidance on 
Choice of Control Group and Related Design and Conduct Issues in Clinical Trials, which 
is referred to as ICH E10 [5]. The ICH E10 guideline provides some general principles for 
the selection of appropriate non-inferiority margins. According to the ICH E10, the 
selection of the non-inferiority margin should be based on both statistical reasoning and 
clinical judgment. The ICH E10 also points out that the selection of the non-inferior ity 
margin should be based on historical experience in placebo-controlled trials, and be 
suitably conservative about the effect size of the active control derived from previous 
placebo-controlled trials. However, the ICH E10 only provides general principles on the 
selection of NI margin and there are no specific standards for the determination of NI 
margin, which can give rise to controversial issues in the research process, such as the 
possibility for the researchers to twist the NI margins to make their studies feasible, while 
at the same time remaining able to justify the selection of the NI margin even when it is 
not reasonable due to the lack of clear guidance or recommendations. 
Some regulatory authorities have attempted to provide guidance regarding the 
choice of the NI margin in specific therapeutic areas, and researchers have conducted much 
exploration into the best approach. A recent U.S. Food and Drug Administration (FDA) 
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guidance on NI trials specifically states that determining the NI margin is the ‘single 
greatest challenge’ as it ties closely into assay sensitivity and is based on the constancy 
assumption regarding the effect of active control in the NI trial [6]. The constancy 
assumption states that the control treatment will show the same measurable efficacy versus 
placebo in the current trial as it did in the historical trials. The FDA guidance presents a 
more concise approach to the choice of margin that can be easily understood by general 
audiences, involving both statistical reasoning and clinical judgment, stating that NI trials 
are designed to show that any difference between the test drug and the active control is 
small enough to allow one to conclude that the test drug has at least some effect or an effect 
that is not too much smaller than that of the active control [7]. When designing a non-
inferiority trial, the effect size of the active control compared with the placebo needs to be 
estimated on the basis of historical data from previous trials. This effect size is called M1. 
Once this number is available, clinical judgment can be used to define the non-inferior ity 
margin (M2), the largest loss of effect relative to the active control that is clinica l ly 
acceptable. Even though M2 can be as large as M1, it is more scientifically meaningful to 
choose an M2 that is a fraction of M1 which is also clinically acceptable. In short, the non-
inferiority margin should be no larger than the threshold of clinical relevance as well as 
being small enough to exclude placebo.  
The FDA also describes a method to select the NI margin [8]. First, the total 
assumed effect of the active comparator over the placebo must be estimated, and a 
conservative estimate of this effect should be taken to ensure that the test drug has an effect 
that is greater than zero. This conservative estimate can be the lower limit of the confidence 
interval of the difference in effect when comparing the active control with the placebo. 
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Although conservative, this minimum treatment effect helps to protect against an 
overestimation of the assumed active control’s effect, leading to a poor choice of the NI 
margin. Second, a preserved fraction of the estimated effect should be determined 
demonstrating that the treatment is not unacceptably worse than its active comparator based 
on clinical judgement.  
Several factors can affect the choice of an NI margin. One potential factor is the 
baseline risk in the control group of the trial. Another candidate factor that may influence 
the NI margin is the type of outcome. Indeed, a previous exploratory study [9] showed that 
the NI margin should be significantly lower when mortality was the primary outcome. 
Moreover, if the treatment reduces mortality, the life expectancy of the patient may also 
play an important role because people may be less willing to accept an increase in mortality 
if the patient still has many years of life left. Because both mortality and average life 
expectancy may vary by disease area, customary NI margins may also vary across different 
disease areas. Another candidate factor that may affect the selection of the NI margin is the 
type of benefit of the test treatment. If the test treatment has other benefits that the control 
does not, including being much less costly, causing fewer side effects, or being less 
invasive, both the clinical practitioners and the patients may be willing to accept the test 
treatment even when its efficacy is not as large as another treatment. The loss of the 
effectiveness could be offset by other benefits of the test treatment that patients are more 
concerned about.  
However, there are also invalid factors that affect the selection of the NI margins. 
When investigators expect that there would be recruitment difficulties, for example trials 
on pediatric patients, or the budgets would be tight due to insufficient funding, they may 
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be willing to accept a larger loss of efficacy and thus a larger NI margin. A larger NI margin 
implies a smaller sample size, and a larger margin may make a trial more feasible with 
limited resources. A larger NI margin also makes the NI trial less conservative by tending 
to produce false positive results, saying that the test treatment is not inferior to the control 
while the test treatment is in fact inferior to the control. Meanwhile, small sample size 
would make the study under-powered. The detectable difference between the two treatment 
groups increases, and a larger NI margin is then selected to ensure that the difference 
between the two groups could still be captured and detected, thus making it easier to get 
the conclusion that the test treatment is not inferior to the control. These are not the correct 
ways to select the NI margins, but these factors generally affect the process of the selection 
of the NI margins often.   
There is little uniformity on how to determine the NI margin when designing or 
interpreting a non-inferiority trial. Some researchers would select the NI margin based on 
the effect of the control treatment against placebo or even on the lower confidence limit of 
the effect’s estimate. But this approach can lead to conclusions that are difficult to justify; 
for example, the more effective the standard treatment, the larger the loss of effectiveness  
that would be accepted in a non-inferiority trial simply to remain better than placebo. 
Others might select the NI margin depending on the severity of the primary endpoint, with 
a smaller NI margin when mortality, disability or other serious events of interest are used. 
The FDA has also proposed a loss of effectiveness of 10% in absolute terms as compatible 
with non-inferiority for anti-infectious or antiretroviral therapies [10]. However, such a 
simple rule is not easily applicable to all disease areas and is not related to the advantages 
of the test treatment. More recently, the FDA and the European Medicines Agency (EMA) 
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have proposed to select the value that preserves at least 50% of the effect of standard 
treatment compared with the placebo [11], but this is a liberal approach and could lead to 
unreasonably wide NI margins. Additionally, in their guidelines for trials in certain 
therapeutic areas (such as diabetes mellitus and infectious diseases), the FDA and EMA 
provide more explicit guidance on how to design a non-inferiority trial. What is surprising 
is that there are discrepancies between the FDA and EMA in the guidelines that recommend 
a specific non-inferiority margin. For example, in the 2008 draft FDA guidance for diabetes 
mellitus, a non-inferiority margin for HbA1C reduction is suggested to be 0.3% or 0.4%, 
while the 2011 EMA guideline suggests a non-inferiority margin of 0.3% [12]. A difference 
of 0.1% of HbA1C may not be clinically meaningful or useful, but this difference will 
result in totally different sample size calculations across non-inferiority trials. In practice, 
the non-inferiority margin, is often “negotiated” between the sponsor of the trial and the 
regulatory agencies. This happens because the threshold of clinical relevance is very 
difficult to determine, and as one European regulatory assessor pointed out during a 
scientific advice meeting, “a smaller margin would have been better” [13], which is of 
course true for any non-inferiority margin.  
Although the selection of the NI margin is complicated, its choice influences the 
outcome interpretation of the NI trial. Setting an inappropriate margin may result in 
inappropriate conclusions. In NI trials, a test treatment may be approved for marketing due 
to the significant benefits, such as it being less toxic, being easier to administer, or being 
less expensive, even if it is less effective than the standard control. A non-inferiority margin 
that is too wide may jeopardize the results as well as diminish the power of the study by 
producing a false positive result and saying that the test drug is not inferior to the control 
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while in fact it is inferior to the control, and encourage acceptance and use of less effective 
therapies, thus resulting in serious injuries to patients. Interpreting the results of an NI trial 
requires an assessment of the rationale for the design and the assumptions underlying the 
choice of the non-inferiority margin. Because the choice of the margin is to some extent 
arbitrary, researchers may be tempted to redefine the margin once the results are in, to 
claim non-inferiority. The margin must be prospectively defined at the start of the study 
using both statistical methods and clinical judgement. Previously it was found [14] that in 
22% of the non-inferiority trials examined, the choice of the non-inferiority margin was 
based merely on the judgements made by the investigators, such as margins that could 
cause clinical difference, or selections that were used in previous NI trials.  
In many situations, the NI margin is simply stated but not justified. A previous 
study [15] found that NI margins vary between medical specialties, but the reasons for this 
phenomenon are unclear. As a result, little is known about the reasoning that researchers 
use in selecting the NI margin. Furthermore, whether researcher-selected NI margins 
reflect patients’ priorities is unclear. In this review, we will summarize the selection of 
non-inferiority margins in general NI trials and explore the extent of variation in NI margin 
selection, in the hope of obtaining the underlying pattern of NI margin selection and giving 
some applicable recommendations to guide the determination of NI margins when 
designing non-inferiority trials.  
Methods  
Literature Searching 
To identify potential non-inferiority trials for analysis, I pre-specified several 
disease domains where non-inferiority trials are likely to be conducted. The areas of stroke 
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and cardiovascular disease were chosen as representatives of circulatory diseases, where 
patients’ conditions are generally serious or acute, and superiority trials with placebo 
control are unlikely to be considered. Meanwhile, superiority trials with active control in 
both areas are usually not the primary goal of investigating test treatment when the actual 
purpose is to prove that the test treatment is equivalent or at least not worse than the existing 
treatment while perhaps having other benefits. Diabetes was chosen as a category of 
endocrine disease as well as chronic disease, and with the reason that diabetes has long 
been a global public health concern [16]. More than 415 million people are living with 
diabetes and 5 million deaths are attributable to diabetes globally [17]. New treatment 
methods are continuously brought up and evaluated using clinical trials, especially non-
inferiority trials when most test treatments have similar efficacy to existing treatments but 
are less costly to reduce the health expenditure due to diabetes for both patients and society. 
Pneumonia and influenza were chosen as categories of infectious and acute diseases, where 
the non-inferiority margins are relatively more well-established. By further reviewing and 
investigating the NI margins that researchers used in published trials, I can examine the 
extent to which the recommendations are in fact followed in trials, in the hope of 
standardizing the selection of NI margins for infectious diseases and bringing up with some 
consistent guidelines in the selection of NI margins that researchers could follow.  
Records of non-inferiority trials were searched on ClinicalTrials.gov, with the 
search terms being “non-inferior” or “noninferior” or “non-inferiority” or “noninferiority”. 
Four independent searches were done, one each the four different disease domains 
described above. For each search, the basic search terms to select NI trials were retained, 
and the “Conditions” area in “Advanced Search - Targeted Search” was additiona lly 
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specified as “stroke” for the stroke domain, “cardiovascular or coronary” for the 
cardiovascular disease domain, “diabetes” for the diabetes domain, and “pneumonia or 
influenza or flu” for the infectious disease domain. The records were screened on 
ClinicalTrials.gov for eligibility. Trials were included if they met all of the following 
criteria: the trial was completed by the time I conducted my search, the trial design was 
non-inferiority, the trial focused on one of the four disease domains, and corresponding 
publications were attached. The first 20 records in each domain with identified publicat ions 
either for the protocol or the final report were included, in consideration of the limited time 
and resources I have for this study. The publications were then retrieved and downloaded 
from PubMed or the source journal for future review.  
Data Extraction 
The primary outcome of interest for my work was the non-inferiority margin used 
by the trials. During the full text review process, the following information was also 
collected as factors potentially related to the selection of the NI margin in each non-
inferiority trial: disease area, whether the study was randomized, phase of the trial, 
blinding/masking status, test treatment and control, number of treatment arms, whether the 
study was placebo controlled, country or region the study was conducted, trial duration, 
participants’ age range, sample size, primary and secondary endpoints, primary analysis 
method and significance level, comparison statistics (measures of association), absolute 
effect sizes of both the test treatment and control, and the rationales on how the trial 
selected its NI margin. The collected information and variables were then aggregated and 




Descriptive statistics were used to report the count as well as the proportion of non-
inferiority trials with specified characteristics. The NI margins collected from different 
trials were often reported in different scales – absolute scale, relative scale, and hazard ratio 
scale. The absolute scale means that the NI margin is expressed as the absolute difference 
between the observed values of the two treatment groups, and the unit of the NI margin is 
the same as the unit of the outcomes. For example, in a study of COPD (chronic obstructive 
pulmonary disease), an outcome might be the observed value of trough forced expiratory 
volume in 1 second (FEV1) at the end of a treatment period and the values usually lie 
between 1000ml to 1500ml.  A NI margin of 50ml to evaluate the difference between the 
groups would be in an absolute scale. The relative scale means that the NI margin is 
expressed as a ratio comparing the two treatment groups. Using the above COPD study as 
an example, a NI margin of 0.8 comparing the value of FEV1 in the test treatment group 
to that in the control group would be on a relative scale. The hazard ratio scale means that 
the NI margin is expressed as a hazard ratio between the two treatment groups, with the 
study outcome measured as the time-to-event. To make the scales as consistent as possible 
and facilitate the comparisons of NI margins between studies, I transformed NI margins in 
absolute scales into relative scales using the effect size that the study reported for the 
control group. The transformation was done as follows: NI margin on relative scale = (NI 
margin in absolute scale + effect size of the control)/effect size of the control. While the 
NI margins in hazard ratio scale incorporated time, they could not be simply transformed 
as above, and were analyzed independently. For both scales, either relative scale or hazard 
ratio scale, the mean and 95% confidence interval for NI margins were calculated within 
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each disease domain as well as across different disease domains to evaluate the variation 
of NI margins. All analyses were conducted using StataSE 14.1 (Stata Corp LP, College 
Station, TX, USA). 
Results  
Among the 80 non-inferiority trials identified and reviewed, I excluded 6 trials from 
further study because the non-inferiority margin was not described (2 trials), or the trial 
was stated to be non-inferiority but the statistical analyses that the researchers fina lly 
conducted were superiority (4 trials). The remaining 74 trials were retained and their 
general characteristics are described in Table 1. As shown, most trials were randomized 
(98.6%), with just one study being an observational matched case-control study conducted 
in the Netherlands. Many trials had only two treatment arms (89.2%) without a placebo 
control (96%), presumably because trying to prove that the test treatment is not worse than 
placebo is the same as trying to prove that the test treatment is not worse than nothing, 
which would be of minimal scientific significance. The masking status of the trials varies, 
with nearly a third of them (32.4%) being open-label and a quarter of them (24.3%) being 
double-masked (both subject and investigator). The decision whether to mask or not in a 
trial heavily depends on the treatment arms and outcomes of interest. When the treatments’ 
distinguishable characteristics – including route of administration, unique patients’ 
reactions – are easily to discern, masking is not feasible. Subjective outcome measures 
benefit from masking to minimize information bias, while objective outcome measures 
may not call as heavily for masking. Almost eighty percent of the trials (79.7%) didn't 
report or indicate their study phase, and among those that did, most were phase III trials, 
meaning that the efficacy or effectiveness of the new treatment is being evaluated. 7 trials 
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(9.5%) were conducted on children, 53 trials (71.6%) were conducted on adults, and 14 
(18.9%) of them did not have age limitations for including participants. Nearly half of the 
trials (46.0%) were performed multi-nationally, with multiple clinical sites across different 
countries or regions. The purposes of conducting multi-center trials are to enlarge sample 
size and include a heterogeneous population that helps assure that results will be 
generalizable. 36 of the 74 trials (48.6%) were analyzed using an intention-to-treat 
approach, in which patients are included into the analyses as randomized.  In superiority 
trials, intention-to-treat analysis is unbiased, because it keeps the randomization intact and 
analyzes as the patients were randomized regardless of what the patients did. By ignoring 
the potential cross-overs between the test treatment and the control which would make the 
two treatments look more similar, the intention-to-treat analysis in superiority trials is 
underestimating the effect size of the test treatment compared to the control and being 
conservative. In non-inferiority trials, however, by ignoring the potential cross-overs which 
would make the two treatments look more similar, it’s easier to get a conclusion that the 
test treatment is not inferior to or different from the control, which is a positive result for 
NI testing and thus is less conservative. 15 of the 74 NI trials (20.3%) were analyzed in the 
per-protocol population (as-treated). In a per protocol analysis, patients are analyzed as the 
treatment they actually receive, which may be biased but is truly conservative for non-
inferiority testing and is the recommended primary analysis method for non-inferior ity 
trials [18]. The statistical significance level for most trials (94.6%) are two-sided 95% or 
one-sided 97.5% with type-I error 𝛼=0.05.  
Table 2 presents the NI margins and the potential correlating factors that may be 
associated with the selection of NI margins for the 74 NI trials. 19 trials are focused on 
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stroke, 20 trials are for cardiovascular diseases, 16 trials are for infectious diseases 
(including pneumonia as well as influenza), and 19 trials are in diabetes. Among the 74 
total NI trials, 82 primary outcomes of interest were identified, due to the fact that a single 
trial might report multiple primary outcomes and have multiple corresponding non-
inferiority evaluations. There are three types of measurements regarding primary outcomes: 
measured as binary (n=35, 42.7%), as continuous (n=38, 46.3%), and as time to event (n=9, 
11.0%). For the 35 primary outcomes measured as binary (the proportion of participants 
that display the outcome), the efficacy of the test treatment is almost always represented as 
the absolute difference between the two proportions of outcome in the treatment arms, 
except for one stroke trial that used risk ratio (RR) as the measure of association. For the 
38 continuous outcome variables, they could be reported as the observed true value (n=22, 
57.9%), the change from baseline (n=15, 39.5%), or the percentage change from baseline 
(n=1, 2.6%). The efficacy of the test treatment is measured as the difference between 
treatment arms, except for 8 diabetes trials that used the ratio of continuous outcome 
variables between treatment groups as the measure of association. For all of the 9 time-to-
event outcomes of interest, hazard ratio was used to compare the efficacy of treatments, 
and all of the time-to-event outcomes were used within the circulatory disease area (stroke 
and cardiovascular disease).  
Stroke Trials 
19 trials were conducted in the stroke area, with the primary outcome variables 
differing widely between studies. In the trials using time-to-event outcome variables and 
hazard ratio as the comparison statistic (n=8, 42.1%), the endpoints of interest were 
generally time to stroke or time to a composite of endpoints including stroke. The NI 
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margins for hazard ratio had a wide range, between 1.05 and 2. The trial with the largest 
NI margin had the smallest population sample size (700) and an intermediate study duration 
(1.5 years), while the trial with the smallest NI margin had the largest population sample 
size (19000) and the longest study duration (2.5 years). A larger sample size and a longer 
trial duration will generally improve the power of a study and make it possible to detect a 
smaller effect difference between treatment groups, thus a smaller NI margin could be 
detected when the NI margin is decided in advance. The mean of the NI margins expressed 
as hazard ratio was 1.43, which is kind of high for a serious outcome. It indicated that the 
test treatment was not inferior to the control treatment if the hazard for stroke (or other 
outcome) in the test treatment group was at most 43% higher compared with the hazard of 
stroke in the control group. The 95% confidence interval for the NI margins expressed as 
hazard ratio ranged between 1.24 and 1.62. Of the 8 stroke trials using binary outcome 
variables (n=8, 42.1%), only one trial adopted the risk ratio as the comparison statistic and 
its NI margin was 1.14 with the primary outcome defined as occurrence of death or 
disability. The other 7 trials used a proportion difference as the comparison statistic, and 
the NI margins were between 2% and 3% when the outcome was a composite of first stroke 
or death, which had a relatively low incidence in the population. The NI margin was large 
(20%) when the outcome was a secondary stroke, which had a high incidence in the study 
population – children with sickle cell anemia who already had a previous stroke. For the 
trials focusing on acute stroke remission, NI margins were all 10% regardless of the 
population size. The remaining 3 trials had continuous outcome variables, and their NI 




20 non-inferiority trials were analyzed in the cardiovascular disease area with 23 
identified primary outcome variables. Only one trial applied a time-to-event outcome 
variable and the NI margin it used was a hazard ratio of 1.3, while its endpoint of interest 
was a composite of cardiovascular death, nonfatal myocardial infarction or hospitaliza t ion 
due to unstable angina. All analyzed studies on coronary artery disease (n=8) utilized in-
stent late lumen loss as the primary endpoint, which was a continuous variable measured 
as the observed value and the comparison between treatments was shown through the 
difference of the losses in both groups. Two trials used 0.20mm as the NI margin, three 
trials used 0.25mm, two trials used 0.32mm, and one trial used 0.11mm. The three trials 
with target lesion failure as the primary endpoint had similar trial durations of around one 
year. Their NI margins ranged from 3.5% to 8.6%, and again the trial with the largest 
sample size had the smallest NI margin, while the trial with the smallest sample size had 
the largest NI margin. Two trials chose vessel revascularization as the primary endpoint, 
and the trial with a larger sample size had a smaller NI margin while they shared the same 
trial duration. Among the five trials using MACE (major adverse cardiac events, defined 
as adjudicated death, myocardial infarction (MI), or clinically driven target vessel 
revascularization) as their primary outcome, I again observed that larger trials tend to have 
smaller NI margins. Sample size in this group ranged from 900 to 2800, with corresponding 
NI margins ranging from 1.5% to 6.0%. There was one trial with two different NI margins 
for the MACE outcome, each for a different active control. The remaining cardiovascular 
trials had unique outcomes and the corresponding NI margins differed significantly due to 




5 non-inferiority trials on pneumonia treatment were identified, two of them using 
treatment failure as the primary outcome, and their NI margins were 7% and 8%. One trial 
used clinical response rate with the NI margin being a 15% absolute proportion difference, 
one trial used mortality from any cause with the NI margin being a 10% proportion 
difference, and the final trial used length of hospital stay with the NI margin being 1 day 
longer. These trials were generally short-term with trial durations between two to four 
weeks. For three trials on COPD (Chronic Obstructive Pulmonary Disease), an endpoint of 
FEV1 was used in two of them, and the NI margins were 50mL and 60mL respectively. 
The third trial used as its outcome the percentage of patients with at least one exacerbation 
within 6 months after the index exacerbation, and its NI margin was 15%. Among the 13 
endpoints reported for NI trials on influenza vaccine, GMTs (geometric mean titers) and 
seroconversion rate were consistently used to evaluate the efficacy of vaccine. A GMT 
ratio of 1.5 was selected as the NI margin for all of 7 trials regardless of any other factors, 
except for one trial with a ratio of 2 as the NI margin. For 6 trials reporting the 
seroconversion rate, a uniform 10% difference was used for all of them. One additiona l 
trial that reported sero-protection rate also utilized a 10% difference as its NI margin.  
Diabetes Trials 
19 non-inferiority trials were analyzed in diabetes, most of which (n=13, 68.4%) 
used the change in HbA1c from baseline as the primary outcome and the absolute 
difference in the changes between the treatment groups as the comparison statistic. The NI 
margins ranged from 0.3% to 0.5% as absolute values, and the most common NI margin 
was 0.4% which appeared in 7 out of 13 trials. Other NI margins included: 0.3% used in 
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two trials, 0.35% used in one trial, 0.45% used in one trial and 0.5% used in two trials. The 
2011 FDA guidance on anti-diabetic drugs included the recommendation of a non-
inferiority margin of 0.3% HbA1C [19]. Achievement of HbA1c level <=7% was also 
employed as a binary primary outcome in two trials, and the NI margins were 5% and 7.68% 
proportion difference in those two trials. A few other outcome variables measuring blood 
glucose for evaluating diabetes treatments were identified, and their study design features 
as well as their NI margins are displayed in Table 2. 
Overall  
After transforming the various scales of comparison statistics into relative scales as 
discussed earlier, I analyzed a total of 47 NI margins on relative scales out of the origina l 
74 NI trials: 11 NI margins in the stroke area, 15 in the cardiovascular disease area, 16 in 
the respiratory disease area, and 5 in the diabetes area (Figure 1). The remaining NI trials 
were excluded or could not be transformed properly because of the following reasons: the 
trials used hazard ratio as the comparison statistic (9 trials); the trials had the effect size in 
either group being zero (13 trials); the trials didn’t provide any information on either the 
hypothesized or actual effect sizes of the treatment groups (4 trials); or the trials had a NI 
margin that exceeded the actual effect size of the active control group with benefic ia l 
outcome (2 trials). Because most of the diabetes trials used the change in HbA1c from 
baseline to the end point as their primary outcome, and the value of change in both groups 
could sometimes be zero, it was impossible to calculate the ratio of the two changes when 
denominator may equal to zero, so these trials were excluded. There were 5 transformed 
NI margins from other trials that used other outcome measures in diabetes. We can see 
from figure 1 that relative NI margins aggregate between 1 and 2 overall, with the margins 
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for diabetes being the least variable and the margins for infectious disease being the most 
variable. The mean of the NI margins for diabetes was 1.24, with a 95% two-sided 
confidence interval from 1.11 to 1.36. The relative smaller variation in the margins for 
diabetes is partly due to the well-established guidelines on the selection of NI margins in 
diabetes trials, which give clear recommendations on the values that researchers could use 
as the NI margins. The mean of the NI margins for cardiovascular disease was 1.50, with 
a 95% two-sided confidence interval from 1.38 to 1.62. The mean of the NI margins for 
stroke was 1.38, with a 95% two-sided confidence interval from 1.23 to 1.53. The mean of 
the NI margins for infectious disease was 1.38, with a 95% two-sided confidence interva l 
from 1.25 to 1.52. It's surprising that a slightly wider confidence interval and more 
variability in the NI margins were identified for infectious disease, while in reality the 
guidance on the selection of the NI margins for infectious disease is much more well-
established compared to other disease areas and clear recommendations have been given 
out in guidance from both FDA and EMA. This phenomenon might result from the diverse 
severity of the outcome indicators, ranging from the mildest (such as cure or clinica l 
response from pneumonia) to the most severe (such as mortality). The severity of the 
outcome assessed is an accepted reason to alter the NI margin. I find that the means of the 
NI margins for different disease domains are similar and the widths of their confidence 
intervals are nearly the same. Pooling all the trials across different disease areas together, 
I found a mean of 1.41 and a 95% two-sided confidence interval from 1.33 to 1.48 for the 
NI margins (Table 3).  
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Rationales for the Selection of NI Margins 
About half of all the trials reported their rationales for selecting a specific non-
inferiority margin (Table 4). Among the rationales stated, the most often cited reasons for 
selecting the NI margin were clinical judgement (18.6%) and guidelines’ recommendation 
(18.6%). Clinical judgement refers to the NI margin that would be considered clinica l ly 
meaningful or significant to both retain the efficacy of test treatment and prove its non-
inferiority to the control. 14.0% of the trials selected the NI margins based on the margins 
that were used in previous trials, which demonstrated the importance of having reference 
trials. For NI margins based on the difference between active control and placebo in 
previous trials (14.0%), various methods were used to decide on the margin, including half 
of the difference, lower bound of the 95% two-sided confidence interval of the difference, 
or half of the lower bound [20]. For NI margins based on the difference between test 
treatment and placebo as well as the difference between active control and placebo in 
previous trials (11.6%), and those based on the effect sizes of both test treatment and active 
control in observational studies, the NI margin was selected as the difference between the 
two differences (for randomized trials) or between the two effect sizes (for observationa l 
studies). Other rationales reported included variance of the outcome measurement, expert 
opinions, and statistical concerns, and were reported in only a few trials.  
Discussion  
In most of the reports, the rationale behind the chosen NI margin was unclear. Tsou 
et al found that it was unclear how the NI margin was determined for 85% of his reviewed 
articles [21]. None of the methodological articles referred to as a source for the NI margin 
contained an exact margin, and none of the previous NI trials referred to contained an 
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explanation or calculation for the margin. A 2005 review of 332 NI trials identified in 
extensive literature searches [22] found that only one-fifth of the non-inferiority studies 
provided an adequate rationale for the selection of the non-inferiority margin. A study of 
the reporting quality of NI trials published from 2003 to 2004 [23] found that fewer than 
20% of the studies reported a clinical consideration and a justification for the margin. In 
this latter study, the non-inferiority margin was reported in all but a few of the articles. In 
a cross-sectional study of a random sample of 232 published non-inferiority trials [24], 
45.7% reported the method by which the margin was determined and 40.9% of the trials 
with rationales justified the choice of the NI margin using clinical relevance. The design 
of a non-inferiority trial requires a trade-off between the possible loss of effectiveness and 
the benefit of the tested treatment. Another reason for not stating the rationale for the 
selection of the NI margin also includes the different balancing of priorities between 
researchers and patients. Sankoh et al also found that the margin was missing more 
frequently in published articles than in unpublished ones, although many of these studies 
were published more recently after guidance on the transparent reporting of such trials had 
become available [25]. Journals and authors should be encouraged to improve the reporting 
on the design and results of NI trials, including information on the rationale of choice for 
the NI margin and the presentation of the results.  
Determining the NI margin implies essentially a trade-off between the possible loss 
in effectiveness and the perceived advantages of the new treatment from the patient 
perspectives. Statistical computations should be performed after the NI margin has been 
determined, after which feasibility can be assessed. After the study is completed, 
conclusions from non-inferiority trials are based on the judgment of investigators regarding 
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the NI margin, which may or not correspond to the judgment of patients and clinicians in 
shared decision making. Thus, constraints regarding logistical and financial burdens should 
not be included in the reasoning to determine the NI margin, as it should not usually bear 
on clinical decisions. As with any other study design, reaching an appropriate sample size 
is important in non-inferiority trials. Even for a treatment that is already significantly non-
inferior, the closer the boundary of the confidence interval is to the pre-specified NI margin, 
the more the decision will be about balancing between the potential loss in effectiveness 
and the advantages of the new treatment.  
No significant association was observed between severity of disease and the range 
of NI margins. Intuitively, one would prefer to select a smaller margin for trials involving 
more-serious diseases, given the potential for increased morbidity and mortality rates 
associated with a less effective drug. If a disease is severe, it is unfavorable to lose much 
of the effect, even if the costs and the adverse events of the new treatment are lower. Larger 
margins may cause less concern in trials involving less severe diseases in which treatment 
failures may not translate into important excess morbidity or mortality. For less severe 
diseases, the willingness to lose some effect for other benefits might be a reasonable trade 
off. Therefore, severity of disease could be included in the decision-making process 
guiding the selection of the NI margin. I did observe that the NI margin was smaller when 
the primary endpoint was mortality compared with treatment failure, which seems logical 
as the acceptability of one additional death is usually lower than the acceptability of one 
additional treatment failure. In a recent experimental study among experts in orthopedic 
surgery [26], the NI margins reported were also small with median NI margin for risk 
difference of 1.8% and median NI margin for relative risk of 1.3. The selection of a margin 
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that is inappropriately large means that the test drug in question may be considerably less 
effective than the control drug, and it could even be no more effective than placebo. 
Conversely, with a smaller margin, clinicians have more assurance that a new drug is not 
inferior to the control agent.  
The Division of Anti-Infective Drug Products of the FDA published 
recommendations [27] on the selection of margins for non-inferiority trials, stating that to 
establish non-inferiority for a test drug compared with control agent, the statistical analysis 
of an anti-infective drug trial should employ a 2-tailed 95% CI around the difference in 
outcomes. One approach to setting the lower bound of the 95% CI would be to base this 
limit on the success rate achieved in the trial. The recommendation was for use of 10%, 
15%, and 20% deltas in trials with success rates of 90%, 80%–89%, and 79%, respectively. 
Since then, the majority of comparative trials is this disease area have used this so-called 
“step function” for selecting their margins [28]. The ICH thus recommends [29] that 
investigators base the selection of margins first on the magnitude of benefit of any therapy 
over placebo or no treatment in randomized controlled trials involving the disease in 
question. If the magnitude of such an effect is known and is sufficiently large, then one can 
select the non-inferiority margin based on the acceptable potential loss of efficacy over 
existing therapies. The determination of the benefit of therapy over placebo should come 
from actual data, but the determination of what constitutes an acceptable potential loss of 
efficacy, relative to existing therapies, is based on clinical judgment. The ICH guidelines 
implicitly recommend disease-specific selection of margins. However, a disease-specific 
approach raises the question of how to select margins for clinical trials in which the exact 
magnitude of the benefit of therapy may be unclear. The questions also arise of what 
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elements of clinical judgment are important in selecting NI margins and how these 
elements should be applied for diseases of varying severity. With use of smaller margins, 
the sample size for the trial increases. This may have implications on the ability to perform 
a trial above and beyond the time and monetary considerations. For a relatively rare, serious 
disease with a low cure rate, the number of patients needed to perform the trial with a 
smaller margin could even exceed the number of patients who have that disease diagnosed 
annually in the United States.  
Vaccine trials are unique among infectious disease trials because most vaccines are 
highly effective and work to prevent disease. For preventive interventions, a small NI 
margin might be preferable because losing a large part of the effect on efficacy or 
immunogenicity is undesirable. Donken et al found that many vaccine studies used an NI 
margin of 10% for the difference (66%) and 0.67/1.5 or 0.5/2.0 for the GMT ratio (94%), 
as suggested in guidelines [30]. Although in most cases the margins used were in line with 
the recommended margins, only 6% of the articles stated that they followed either EMA or 
FDA guidelines. The differences and the variability in NI margins used might be because 
of the lack of clear and explicit guidelines on which NI margin to use for vaccine trials. It 
is also questionable whether all vaccine trials should use the same NI margin. Examples of 
possible factors to consider are the severity of disease, side effects, potential benefits of the 
new vaccine, the aim or study objective and the quantity and quality of the immune 
response. It is important to choose the NI margin in a way that coverage or percentage 
protected in the total population will be sufficient to prevent the spread of the disease.  
Determination of the NI margin could be simplified by better and more explic it 
guidelines from the regulatory authorities. An improved approach might be to employ the 
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FDA method of using a preserved fraction if the study design allows this. A preserved 
fraction of 50% has become common practice in non-inferiority trials (e.g. cardiovascular, 
and irreversible morbidity), while higher fractions have been used in other disease areas 
(e.g. 90% preserved fraction in antibiotics). However, problems also arise from this 
approach. For example, consider an attempt to prove that drug B is not inferior to drug A 
(active comparator), and the effect size of drug A from previous placebo-controlled trials 
is 60%, which indicates that drug A will show effectiveness in 60% of the patients. By 
using a preserved fraction of 50%, we have the NI margin as 30%, meaning that an effect 
size as low as 30% for drug B is enough to conclude that drug B is not inferior to drug A. 
Then, consider if drug B is widely used while drug A is withdrawn from the market and no 
longer available. If we now test a new NI trial trying to prove that drug C is not inferior to 
drug B, and based on the effect size of drug B being 30% and a preserved fraction of 50%, 
an effect size as low as 15% for drug C is enough to prove that drug C is not inferior to 
drug B. If this situation continues, we would get less and less effective tested treatments 
while the non-inferiority still holds without any obvious violations in the selection of the 
NI margins. To avoid this “chain reaction” and prevent the situation that the effects of the 
tested treatments are shrinking all the way down, one possibility might be to establish a 
starting or fixed value for the NI margin, and then this NI margin could be adapted based 
on the specific characteristics of that NI trial. For example, we could set the NI margin as 
10% for all NI trials in this disease area, and the NI margin in a specific trial could be 
adjusted within the range of 8% to 12%, considering factors including the seriousness of 
the outcome, risk-benefit profile of the active comparator, or whether the effect of the 
active comparator has diminished over time. Another possibility to avoid this “chain 
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reaction” would be to use the same active comparator for all tested treatments, for example, 
to use drug A as the active comparator for the evaluations of both drug B and drug C. 
Limitations  
The primary limitation of my analyses is the potential for publication bias. The 
published trials included in this study may not be representative of all NI trials published 
in the literature. Another limitation of my study is the relatively small sample size. It is 
possible that a larger study, including more trials, might identify predictors associated with 
the selection of non-inferiority margins and confidence intervals or P-values. Finally, the 
process of determining the non-inferiority margin was described only in general terms in 
most published articles. Thus, it was difficult to analyze the reasoning behind the selected 
non-inferiority margin.  
In summary, one should select a margin for a NI clinical trial that allows a high 
degree of certainty that the drug is better than placebo and ensures that any potential loss 
in efficacy compared to an active control is clinically acceptable. With use of a smaller 
margin, one achieves a higher degree of certainty that the efficacies of the drug being 
studied in the trial is indeed non-inferior. However, one must balance the desire for more 
certainty against the current state of knowledge about a given disease, clinical judgment, 
and the practicalities of performing clinical trials including the required sample size. 
Audiences have been introduced to the concepts and terminology of this study design as 
well as to the more detailed issues of conduct and analysis. Regulatory agencies have 
provided guidance and the FDA issued a draft guidance to highlight their current 
recommendations on acceptable approaches to the design and analysis of NI trials. 
Although there is not an established ‘optimal’ approach or design, most parties in the 
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clinical trial community agree that a successful NI trial requires the key elements below: 
appropriate active control, appropriate NI margin, overall assay sensitivity, and limited 
cross-overs.  
In practice, the selection of non-inferiority margins should be based on both 
statistical justification and clinical judgment. More research is necessary on how to 
integrate statistical justification and clinical judgment in the development of non-inferior ity 
margin. In the meantime, it is essential that regulators are aware of the difficulties faced by 
applicants, and scientific dialogue between both parties can support the regulators in 
improving guidance on non-inferiority trials. 
Conclusion 
Generally, it appears arbitrary when researchers select the NI margins for non-
inferiority trials. It appears that they select the NI margins without solid rationales, and the 
NI margins are more like a product under the manipulation in the purpose of making the 
trial feasible to conduct and statistically significant. Difficulties still exist in selecting the 
appropriate NI margin of non-inferiority trials. Straightforward and harmonized guidance 
on the selection of non-inferiority margin is needed. It is unlikely that regulatory guidelines 
can cover all therapeutic areas, either as one general guideline or special sections on non-
inferiority trials in disease-specific guidelines, however, they could be used as an 
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Table 1. Basic characteristics of the included non-inferiority trials (N=74) 
Characteristics No. of trials % 
Randomized    
   Yes  73 98.6 
   No  1 1.4 
Masking    
   Open-label 24 32.4 
   Subject-mask 7 9.5 
   Observer-mask 15 20.3 
   Double-mask 18 24.3 
   No  4 5.4 
   Unknown  6 8.1 
Study phase   
   II/IIb 2 2.7 
   III 9 12.2 
   IV 4 5.4 
   Unknown  59 79.7 
No. of treatment arms   
   2 66 89.2 
   3 8 10.8 
Use of placebo control   
   Yes  3 4.0 
   No  71 96.0 
Participants    
   Children  7 9.5 
   Adults  53 71.6 
   Unknown  14 18.9 
Regions   
   USA 14 18.9 
   Non-USA  26 35.1 
   Multinational  34 46.0 
Primary analysis population   
   ITTa 36 48.6 
   PPb 15 20.3 
   Both  17 23.0 
   Unknown  6 8.1 
Significance level (two-sided)   
   0.05 (95% CIc) 70 94.6 
   0.1 (90% CI) 2 2.7 
   Unknown  2 2.7 
a ITT, intention-to-treat. 
b PP, per-protocol. 
c CI, confidence interval.
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Table 2. Design of the included non-inferiority trials and their non-inferiority margins 





Trial durationb Sample size Definitionc  Typed  Unit  Scale e  CSf  NI margin 
Stroke           
 2 2.5Y; 2Y 2700; 18000  Occurrence of stroke TTE  - - HR 1.33; 1.46  
 3 1.5Y; 1Y; 2.5Y 700; 1600; 
19000 
Composite of stroke, 
myocardial infarction, or 
vascular events 
TTE - - HR 2; 1.25; 1.05 
 3 8M; 10M; 2Y 3700; 4600; 
15000 
Composite of stroke or 
systemic embolism 
TTE   HR 1.38; 1.5; 
1.46  
 3 30D; 30D; 5Y 500; 1200; 
1500 
Stroke or death Bin  % - Dif  2; 2.5; 3 
 1 2.5Y  Occurrence of secondary 
stroke 
Bin  % - Dif  20 
 1 4W 120 P2Y12 percentage 
inhibition  
Con  % 
points 
CB Dif  9 
 1 4W 200 Global CBF change  Con  % CB Dif  8.6  
 1 2Y 120 TCD velocity Con  cm/s Obs  Dif  15 
 1 90D 450 Modified Rankin Scale 
score of 0-2  
Bin  % - Dif  10 
 1 90D 200 Successful recanalization  Bin  % - Dif  10 
 1 90D 110 TIMI scale 2 or 3 flow Bin  % - Dif  10 
 1 90D 3300 Death or disability Bin  % - RR 1.14 






Table 2 (continued) 



























 8 6M; 6M; 6M; 










 3 13M; 12M; 12M 400; 2000; 
2300 
Target lesion failure Bin  % - Dif  8.6; 4.5; 3.5 
 2 9M; 9M 1100; 1800 Target vessel 
revascularization 
Bin  % - Dif  3.6; 3 





MACE Bin  % - Dif  6; 5; 4; 1.5; 
2 and 2.5 
 1 12M 130 Freedom from MACE Bin  %  - Dif  10 
 1 12M 3100 NACCE Bin  % - Dif  2.7 
 1 30D 3750 Composite of cardiac 
deaths, myocardial 
infarction, stroke, or 
major bleeding 
Bin % - Dif 0.75 
 1 30D 70 Inhibition of platelet 
aggregation (%IPA) 
Bin  % - Dif  5 
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Table 2 (continued) 





Trial durationa Sample size Definitionb  Type c  Unit  Scaled  CSe NI margin 
Diabetes           
 1 1D 375 Glycemic control 
measured by mean daily 
BG concentration 
Con  mg/dL Obs  Dif  18 
 1 26W 180 Baseline adjusted HbA1c Con  mmol 
/mol 
Obs  Dif  5.5 
 13 24W; 24W; 
24W; 6M; 6M; 
20W; 28W; 
24W; 24W; 







500; 520; 800 







 2 24W; 24W 320; 970 Achievement of an 
HbA1c level of <=7% 
Bin % - Dif  5; 7.68 
 1 6W 80 Blood fructosamine Con % PB Dif  20 
 1 32W 80 Coefficient of variation of 
FBG 
Con  - Obs  Ratio  1.25 
COPD          
 2 12W; 26W 657; 676 FEV1 Con  mL Obs  Dif  50; 60 
 1 6M 183 Patients with at least one 
exacerbation 
Bin % - Dif  15 




Table 2 (continued) 
























 1 7-14D 300 Clinical responses at test-
of-cure 
Bin  % - Dif  15 
 1 28D 496 Mortality from any cause Bin  % - Dif  10 
 1  130 Length of hospital stay Con  Days  Obs  Dif  1 
Influenza 
vaccine  
         
 7 30 & 180D; 







GMTs Con  - Obs  Ratio  1.5; 2; 1.5; 
1.5; 1.5; 1.5; 
1.5 





Seroconversion Bin   % - Dif  10; 10; 10; 
10; 10; 
 1 30D 300 Sero-protection Bin % - Dif  10 
 
a CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease. 
b Y, years; M, months; W, weeks; D, days. 
c CBF, cerebral blood flow; TCD, transcranial Doppler; TIMI, Thrombolysis in Myocardial Ischemia; MACE, major adverse cardiac e vents, defined as 
adjudicated death, myocardial infarction (MI), or clinically driven target vessel revascularization (TVR); NACCE, net adverse clinical and cerebral e vents, a 
composite of all-cause death, myocardial infarction [MI], stroke, or major bleeding; FEV1, trough forced expiratory volume  in 1 second; GMTs, geometric mean 
titers; BG, blood glucose; FBG, fasting blood glucose. 
d TTE, time to event; Bin, binary; Con, continuous. 
e Obs, observed value; CB, change from baseline; PB, percentage change from baseline. 
f CS, comparison statistic; HR, hazard ratio; Dif, difference; RR, risk ratio. 
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Table 3. Non-inferiority margins on relative scales by disease domain 
Disease domain No. of margins Mean 95% CIa Range  
Stroke  11 1.38 1.23 – 1.53 1.1 – 1.88 
Cardiovascular disease 15 1.50 1.38 – 1.62 1.06 – 1.96 
Infectious disease 16 1.38 1.25 – 1.52 1.04 – 2.00  
Diabetes  5 1.24 1.11 – 1.36  1.08 – 1.43 
Total  47 1.41 1.33 – 1.48 1.04 – 2.00 
 





Table 4. Rationales for the selection of non-inferiority margins in the included NI trials  
Rationales  No. of 
trialsa  
% 
Based on the effect size of active control over placebo in previous trials 6 14.0 
Based on both the effect size of test treatment over placebo and the effect 
size of active control over placebo in previous trials 
5 11.6 
Based on the effect size of active control in previous non-trial studies 1 2.3 
Based on both the effect size of test treatment and the effect size of active 
control in previous non-trial studies 
5 11.6 
Based on the NI margin used in previous NI trials 6 14.0 
Based on the variation of the primary outcome measurement 2 4.6 
Clinically meaningful/significant judgement  8 18.6 
Guidelines/recommendations   8 18.6 
Experts opinions  1 2.3 
Statistically appropriate/feasible 1 2.3 
Total  43 100 
 
a Number of trials is duplicate counting, in which one NI trial may contribute to multiple 
rationales for the selection of NI margin. 
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